Experts discuss radioimmunotherapy for follicular lymphoma

04/26/2013 | Medscape (free registration)

While most experts agree that patients with advanced follicular non-Hodgkin lymphoma who present with symptoms should receive treatment, there are still differing opinions on what therapy to use as first-line treatment, according to an editorial published in the Journal of Clinical Oncology. Research supports the use of rituximab in combination with other drugs, but radioimmunotherapies such as Zevalin and Bexxar also have a potential role in treatment, according to the editorialists. Even with access and reimbursement challenges, these radioimmunotherapeutics are "probably the most effective, yet least used, treatment for follicular lymphoma," according to Dr. Bruce Cheson from the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington, D.C.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC